Justification and Approval Other Than Full and Open - Final_Redacted.pdf

This justification and approval document outlines a sole source contract awarded by the Department of the Army Materiel Command Army Contracting Command Aberdeen Proving Ground. On October 27, 2020, the agency awarded an unknown vendor an undisclosed amount under contract W911QY-21-C-0016 to procure LY-CoV-555 monoclonal antibody therapy for the treatment of SARS-CoV-2. The justification for restricting competition and awarding this sole source contract was the urgent need to secure supply of this treatment during the COVID-19 pandemic. No other details on pricing terms, quantities, or period of performance were provided in this redacted document.